MetaStat, Inc. announced positive preliminary results from a study of MetaSite Breast in patients with ER-positive, HER2-negative early stage invasive breast cancer. The prognostic study met its prospectively defined primary endpoint. It demonstrated the MetaSite Breast Score is significantly and directly associated with increased risk of distant metastasis in ER-positive, HER2-negative invasive breast cancer for both high (>35 MetaSites) versus low (<12 MetaSites) MetaSite scores (OR = 3.4; 95% CI = 2.8-4.1; P=0.0002) as well as between intermediate (12-35 MetaSites) and low MetaSite scores (OR=3.24; 95% CI = 2.6-3.9; P=0.0006).

The MetaSite Breast Score predicted risk of distant metastasis in ER-positive, HER2-negative early stage invasive breast cancer independent of traditional clinical factors. MetaStat plans to submit complete data from this study for presentation at a future medical meeting.